BOSTON, June 15, 2026
Bambusa Therapeutics has announced positive preliminary results from the multiple ascending dose (MAD) cohorts of its Phase 1 clinical trial evaluating BBT002, a next-generation, long-acting bispecific antibody designed to simultaneously target IL-4Rα and IL-5, two clinically validated drivers of Type 2 inflammation. The findings were presented during an oral session at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Turkey, and further strengthen the clinical profile of BBT002 as a potentially differentiated treatment for chronic inflammatory respiratory diseases. The data demonstrated rapid, deep and sustained biologic activity across multiple inflammatory biomarkers, while also showing a prolonged half-life that may enable less frequent dosing and improved patient convenience. As Bambusa advances the therapy into proof-of-concept studies in chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP), the company believes BBT002 could represent a significant innovation in the evolving treatment landscape for Type 2 inflammatory diseases.
BBT002 Demonstrates Strong Biomarker Suppression Across Multiple Pathways
The Phase 1 study results highlighted the ability of BBT002 to simultaneously inhibit multiple drivers of Type 2 inflammation, a hallmark of diseases such as COPD, asthma and CRSwNP. Researchers reported that treatment produced rapid, robust and sustained depletion of eosinophils, a key biomarker associated with airway inflammation and disease exacerbation risk. The therapy also generated dose-dependent reductions in thymus and activation-regulated chemokine (TARC), an important marker linked to Th2-driven immune responses and inflammatory disease activity.
Additionally, BBT002 achieved rapid, complete and sustained inhibition of phosphorylated STAT6 (pSTAT6), a critical downstream mediator of IL-4Rα signaling. Notably, these effects were maintained for more than eight weeks following multiple doses, underscoring the therapy’s potential to provide prolonged biologic activity through dual pathway inhibition. Company executives noted that the consistency of the MAD results with previously reported single ascending dose data further validates the mechanism of action and therapeutic potential of the investigational antibody.
Extended Half-Life Supports Potential for Convenient Dosing
Advertisement
A key differentiator highlighted during the presentation was the favorable pharmacokinetic profile of BBT002. The therapy demonstrated an approximate 29.4-day half-life, supporting the possibility of extended dosing intervals compared with existing biologic therapies. Such a profile could improve treatment adherence and reduce the burden associated with frequent injections, an important consideration for patients requiring long-term management of chronic inflammatory disorders. Safety findings were equally encouraging, with BBT002 reported to be well tolerated across all evaluated dose levels in both the single ascending dose and multiple ascending dose cohorts.
Investigators also observed a low incidence of anti-drug antibodies, with no apparent impact on safety or pharmacokinetics. Collectively, these results suggest that BBT002 may offer a combination of durable efficacy, convenient administration and a favorable safety profile, positioning it as a potentially attractive therapeutic candidate within the rapidly expanding immunology and inflammation market.
Advancing Clinical Development in COPD and CRSwNP
Bambusa Therapeutics is currently evaluating BBT002 in ongoing proof-of-concept studies involving patients with chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP). Topline data from the COPD trial are expected by the end of 2026, while CRSwNP results are anticipated during the first half of 2027. The company believes its bispecific antibody platform, which combines advanced protein engineering with half-life extension technology, has the potential to redefine treatment strategies across multiple inflammatory diseases.
By targeting both the IL-4/IL-13 pathway through IL-4Rα and the IL-5/eosinophil axis within a single molecule, BBT002 aims to deliver broader disease control than single-target biologics. With growing demand for therapies capable of addressing complex inflammatory pathways while reducing treatment burden, the positive Phase 1 findings provide important momentum for Bambusa’s clinical development efforts and reinforce the promise of next-generation bispecific antibodies in respiratory and eosinophil-driven disorders.
Source: Bambusa Therapeutics press release
